Evidence map›Paper›PMID 23943897›Full record

ArticleJournal of oncology practice2013

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

Karen A Autio, Antonia V Bennett, Xiaoyu Jia, Michael Fruscione, Tomasz M Beer, Daniel J George, Michael A Carducci, Christopher J Logothetis, Robert C Kane, Laura Sit and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Karen A AutioMemorial Sloan-Kettering Cancer Center, New York; Weill Cornell Medical College, New York, NY; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Duke University Medical Center, Durham; Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore; US Food and Drug Administration, Silver Spring, MD; and University of Texas MD Anderson Cancer Center, Houston, TX.
Antonia V Bennett
Xiaoyu Jia
Michael Fruscione
Tomasz M Beer
Daniel J George
Michael A Carducci
Christopher J Logothetis
Robert C Kane
Laura Sit
Lauren Rogak
Michael J Morris
Howard I Scher
Ethan M Basch
Johns Hopkins University · USMemorial Sloan Kettering Cancer Center · USUnited States Food and Drug Administration · USCornell University · USOregon Health & Science University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

purposeContemporary tumor-directed therapies for metastatic castration-resistant prostate cancer (mCRPC) are approved to prolong life, but their effects on symptoms such as pain are less well understood as a result of the lack of analytically valid assessments of pain prevalence and severity, clinically meaningful definitions of therapeutic benefit, and methodologic standards of trial conduct. This study establishes pain characteristics in the mCRPC population using a PRO measure. MATERIALS AND

methodsPatients with prostate cancer participated in an anonymous survey at five US comprehensive cancer centers in the Prostate Cancer Clinical Trials Consortium that incorporated the Brief Pain Inventory (BPI), analgesic use, and interference with daily activities. Prevalence and severity of cancer-related pain and analgesic use were tabulated according to castration-resistant status and exposure to docetaxel chemotherapy.

resultsFour hundred sixty-one patients with prostate cancer participated, of whom 147 had mCRPC involving bone (61% [89 of 147] docetaxel exposed, 39% [58 of 147] docetaxel naive). Pain of any level was more common among docetaxel-exposed versus docetaxel-naive patients with mCRPC (70% [62 of 89] v 38% [22 of 58], respectively; P<.001). BPI score≥4 was reported by 38% (34 of 89) of docetaxel-pretreated and 24% (14 of 58) of docetaxel-naive patients with mCRPC; 40% of these patients with pain intensity≥4 reported no current narcotic analgesic.

conclusionPain prevalence and severity were higher in patients with prior docetaxel exposure. Analgesics were underutilized. These results provide a method for estimating accruals along the disease continuum, and for enabling design of trials appropriately powered to assess pain.

Indexed as

AdultAgedAnalgesicsAntineoplastic AgentsBone NeoplasmsDocetaxelHumansMaleMiddle AgedPainPatient Outcome AssessmentPrevalenceProstatic NeoplasmsSelf ReportTaxoidsAnalgesicsAntineoplastic AgentsDocetaxelTaxoids

Identifiers

PMID23943897
PMCPMC3994234
OpenAlexW2139976767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.